• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRCA1 基因内含子 c.5407-25T>A 变异导致外显子 23 部分跳跃-一种可能具有低外显率的致病性变异体?

The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance?

机构信息

Western Norway Familial Cancer Center, Haukeland University Hospital, Bergen, Norway.

Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.

出版信息

Eur J Hum Genet. 2020 Aug;28(8):1078-1086. doi: 10.1038/s41431-020-0612-1. Epub 2020 Mar 20.

DOI:10.1038/s41431-020-0612-1
PMID:32203205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7382492/
Abstract

Rare sequence variants in the non-coding part of the BRCA genes are often reported as variants of uncertain significance (VUS), which leave patients and doctors in a challenging position. The aim of this study was to determine the pathogenicity of the BRCA1 c.5407-25T>A variant found in 20 families from Norway, France and United States with suspected hereditary breast and ovarian cancer. This was done by combining clinical and family information with allele frequency data, and assessment of the variant's effect on mRNA splicing. Mean age at breast (n = 12) and ovarian (n = 11) cancer diagnosis in female carriers was 49.9 and 60.4 years, respectively. The mean Manchester score in the 20 families was 16.4. The allele frequency of BRCA1 c.5407-25T>A was 1/64,566 in non-Finnish Europeans (gnomAD database v2.1.1). We found the variant in 1/400 anonymous Norwegian blood donors and 0/784 in-house exomes. Sequencing of patient-derived cDNA from blood, normal breast and ovarian tissue showed that BRCA1 c.5407-25T>A leads to skipping of exon 23, resulting in frameshift and protein truncation: p.(Gly1803GlnfsTer11). Western blot analysis of transiently expressed BRCA1 proteins in HeLa cells showed a reduced amount of the truncated protein compared with wild type. Noteworthily, we found that a small amount of full-length transcript was also generated from the c.5407-25T>A allele, potentially explaining the intermediate cancer burden in families carrying this variant. In summary, our results show that BRCA1 c.5407-25T>A leads to partial skipping of exon 23, and could represent a likely pathogenic variant with reduced penetrance.

摘要

BRCA 基因非编码区的罕见序列变异常被报告为意义未明的变异(VUS),这使得患者和医生处于一个具有挑战性的位置。本研究的目的是确定在来自挪威、法国和美国的 20 个疑似遗传性乳腺癌和卵巢癌家族中发现的 BRCA1 c.5407-25T>A 变异的致病性。这是通过将临床和家族信息与等位基因频率数据相结合,并评估该变异对 mRNA 剪接的影响来实现的。女性携带者的乳腺癌(n=12)和卵巢癌(n=11)的平均发病年龄分别为 49.9 岁和 60.4 岁。20 个家族的平均曼彻斯特评分(Manchester score)为 16.4。BRCA1 c.5407-25T>A 的等位基因频率在非芬兰裔欧洲人中为 1/64,566(gnomAD 数据库 v2.1.1)。我们在 1/400 名匿名挪威献血者和 0/784 名内部外显子组中发现了该变异。对来自血液、正常乳腺和卵巢组织的患者源性 cDNA 的测序显示,BRCA1 c.5407-25T>A 导致外显子 23 的跳跃,从而导致移码和蛋白质截断:p.(Gly1803GlnfsTer11)。用瞬时表达 BRCA1 蛋白的 HeLa 细胞进行的 Western blot 分析显示,与野生型相比,截断蛋白的量减少。值得注意的是,我们发现从 c.5407-25T>A 等位基因也产生了少量全长转录本,这可能解释了携带该变异的家族中中间的癌症负担。总之,我们的结果表明,BRCA1 c.5407-25T>A 导致外显子 23 的部分跳跃,可能是一种具有低外显率的潜在致病性变异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f7f/7382492/dfb7b0bbd0d3/41431_2020_612_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f7f/7382492/7cbf2034a230/41431_2020_612_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f7f/7382492/dfb7b0bbd0d3/41431_2020_612_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f7f/7382492/7cbf2034a230/41431_2020_612_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f7f/7382492/dfb7b0bbd0d3/41431_2020_612_Fig2_HTML.jpg

相似文献

1
The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance?BRCA1 基因内含子 c.5407-25T>A 变异导致外显子 23 部分跳跃-一种可能具有低外显率的致病性变异体?
Eur J Hum Genet. 2020 Aug;28(8):1078-1086. doi: 10.1038/s41431-020-0612-1. Epub 2020 Mar 20.
2
Screening of deep intronic regions by targeted gene sequencing identifies the first germline variant causing pseudoexon activation in a patient with breast/ovarian cancer.通过靶向基因测序筛选深内含子区域,鉴定了首个导致乳腺癌/卵巢癌患者假外显子激活的种系变异。
J Med Genet. 2019 Feb;56(2):63-74. doi: 10.1136/jmedgenet-2018-105606. Epub 2018 Nov 24.
3
The c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability.c.4096+3A>G 变异在遗传性乳腺癌和卵巢癌中显示出经典的致病性突变特征,但仍允许纯合子存活。
Genes (Basel). 2019 Nov 1;10(11):882. doi: 10.3390/genes10110882.
4
BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients.未解决的遗传性乳腺癌/卵巢癌患者的 BRCA1 和 BRCA2 全长 cDNA 分析。
Cancer Genet. 2021 Nov;258-259:10-17. doi: 10.1016/j.cancergen.2021.06.003. Epub 2021 Jun 18.
5
Identification of a Splice Variant (c.5074+3A>C) of by RNA Sequencing and TOPO Cloning.通过 RNA 测序和 TOPO 克隆鉴定 的剪接变体 (c.5074+3A>C)。
Genes (Basel). 2021 May 26;12(6):810. doi: 10.3390/genes12060810.
6
Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.遗传性乳腺癌和卵巢癌综合征中卵巢、输卵管和原发性腹膜癌淋巴结转移的危险因素。
Jpn J Clin Oncol. 2020 Dec 16;50(12):1380-1385. doi: 10.1093/jjco/hyaa124.
7
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.西班牙东南部穆尔西亚地区遗传性乳腺癌和卵巢癌家族中BRCA1/BRCA2基因变异的分子特征及临床解读:BRCA携带者和非携带者的临床病理特征
Fam Cancer. 2017 Oct;16(4):477-489. doi: 10.1007/s10689-017-9985-x.
8
Identification and Characterization of New Element Insertion in the Exon 14 Associated with Hereditary Breast and Ovarian Cancer.鉴定和特征分析与遗传性乳腺癌和卵巢癌相关的第 14 外显子中新的基因插入。
Genes (Basel). 2021 Oct 29;12(11):1736. doi: 10.3390/genes12111736.
9
Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.多基因癌症panel 检测中内含子变异的外显子剪接分析,用于遗传性乳腺癌/卵巢癌。
Cancer Sci. 2020 Oct;111(10):3912-3925. doi: 10.1111/cas.14600. Epub 2020 Sep 2.
10
The BRCA1 c.5434C->G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements.BRCA1 c.5434C->G (p.Pro1812Ala) 变异通过影响外显子剪接调控元件导致外显子 23 跳跃性缺失。
J Med Genet. 2010 Jun;47(6):398-403. doi: 10.1136/jmg.2009.074047.

引用本文的文献

1
Reclassifying BRCA1 c.4358-2A > G and BRCA2 c.475 + 5G > C variants from "Uncertain Significance" to "Pathogenic" based on minigene assays and clinical evidence.基于迷你基因检测和临床证据,将 BRCA1 c.4358-2A>G 和 BRCA2 c.475+5G>C 变异体从“意义不明”重新分类为“致病性”。
J Cancer Res Clin Oncol. 2024 Feb 1;150(2):62. doi: 10.1007/s00432-023-05597-y.
2
Identification of Spliceogenic Variants beyond Canonical GT-AG Splice Sites in Hereditary Cancer Genes.鉴定遗传性癌症基因中非典型 GT-AG 剪接位点的剪接变体。
Int J Mol Sci. 2022 Jul 4;23(13):7446. doi: 10.3390/ijms23137446.
3
Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic and Variants.

本文引用的文献

1
The molecular basis of partial penetrance of splicing mutations in cystic fibrosis.囊性纤维化中剪接突变部分外显率的分子基础。
Am J Hum Genet. 1997 Jan;60(1):87-94.
病例回顾:全外显子组测序分析鉴定出卵巢癌病例中已知致病性和可能致病性的内含子变异的携带者,这些病例在临床上为阴性。
Genes (Basel). 2022 Apr 15;13(4):697. doi: 10.3390/genes13040697.
4
Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma.酪氨酸激酶抑制剂是治疗HER2阳性猫乳腺癌的有前景的治疗工具。
Pharmaceutics. 2021 Mar 6;13(3):346. doi: 10.3390/pharmaceutics13030346.